Placeholder Banner

Vaccines: 2008 Draft Strategic National Vaccine Plan

March 10, 2016

Draft Strategic National Vaccine Plan, 11/26/08

Preface: Letter from the Assistant Secretary for Health


Given the importance of vaccines and immunizations in the prevention of an expanding
number of infectious diseases, it is important that we – as a Department and as a Nation --
clearly articulate our vision for the vaccine and immunization enterprise. In my role as
the Assistant Secretary for Health and the Director of the National Vaccine Program, I
have directed and monitored the efforts to update the 1994 National Vaccine Plan.

The accompanying draft strategic National Vaccine Plan reflects current priorities and
potential future directions for the next decade. This draft Plan offers a clear signal about
our goals for vaccines and immunizations to our domestic and international partners in
the United States vaccine and immunization enterprise and abroad, both public and
private in the United States and abroad. It is a strong beginning, but requires extensive
consultation with and input from many partners, including the public. This input will
also enable us to develop an implementation plan with discrete activities and measurable
milestones. With release of this draft Plan, consultations with stakeholders will begin,
led by the National Vaccine Program Office and the National Vaccine Advisory
Committee. We all look forward to the final products of these efforts in late 2009.

Download Full Comments Below
National Vaccine Plan
Read the plan
Discover More
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO comments on a proposed rule to restrict planting of GE organisms on national wildlife refuge lands. 
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.